Conclusion. In this limited population, it appears FMT may predispose to weight gain, which may reflect improved health with CDI cure. However, effects of FMT on patient’s microbiome must also be considered. As this intervention becomes more widely used we must be increasingly aware of possible metabolic side effects and ensure documentation of weight changes as part of FMT protocols.

Disclosures. All authors: No reported disclosures.

1262. Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Infections in Patients with Inflammatory Bowel Disease

Teresa Khanal MD1; Zachary Fleischner, MD2; Robert Chow, MD3; Melinda Monteforte, PharmD2 and Luis A. Marcos, MD, MPH4. Infectious Disease, Stony Brook University Hospital, Stony Brook, New York; Internal Medicine, Stony Brook University Hospital, Stony Brook, New York; Infectious Diseases, Stony Brook University Hospital, Stony Brook, New York; Pharmacology, Stony Brook University Hospital, Stony Brook, New York.

Session: 148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM

Background. Fidaxomicin is a narrow spectrum macrocyclic antibiotic used for the treatment of Clostridium difficile infection (CDI). The objective of this study is to compare the recurrence and mortality rates of patients with CDI who received either vancomycin or fidaxomicin at Stony Brook University Hospital.

Methods. A retrospective chart review was performed to identify all hospitalized patients who received fidaxomicin and vancomycin for the period 2011-2015. Inclusion criteria included patient age ≥18 years, stool positive PCR test for C. difficile and being treated ≥10 days of either fidaxomicin or vancomycin orally. Clinical recurrence was defined as a return of diarrhea, a positive test for C. difficile toxin B and a need for retreatment for CDI within 90 days of cessation of therapy.

Results. A total of 55 (52.7% male) and 74 (51.4% male) cases met inclusion criteria in the fidaxomicin and vancomycin arm respectively. Median age was 65.9 ± 1.88 and 63.7 ± 1.86 years in group F and V respectively (P = 0.4). Median length of hospitalization was 14 and 9 days for F and V respectively (P = 0.6). Both groups had similar proportions on the following variables: immunosuppression (V 36.5% vs. F 36.4%, P = 0.9), ≥1 prior episode of CDI (V 59.5% vs. F 61.8%, P = 0.8), sepsis on admission (V 29.7%, F 36.4%, P = 0.4), the use of any antibiotic during the last 30 days (V 74.3%, F 71%, P = 0.7), and treatment with additional anti-CDI therapy (V 24.3%, F 29.1%, P = 0.5). CDI recurrence rate was 24% (V) and 40% (F, P = 0.057). The 90-day mortality rate was 4.1% in the vancomycin group and 10.9% in the fidaxomicin group (P = 0.13).

Conclusion. Fidaxomicin had a higher recurrent CDI rate than vancomycin in this tertiary medical center.

Disclosures. All authors: No reported disclosures.

1263. Factors Affecting Effectiveness of Fecal Microbiota Transplant

Danielle Mosby, MPH; Patty Mcgraw, RN, MS; Chad Duffalo, MD, MPH; Marci Drees, MD, MS; Fedele Defalma, MD; Christine Herdman, MD; Scott Myerson, MD and Alfred E. Bacon III, MD; Christiana Care Health System, Newark, Delaware.

Session: 148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM

Background. Fecal microbiota transplant (FMT) is an effective treatment for relapsing Clostridium difficile infection (CDI). With more widespread use of this intervention, variable cure rates (70~95%) have been observed. We conducted this study to identify specific patient- and procedure-level factors affecting FMT effectiveness, hypothesizing that those patients with higher comorbidity, inadeguate bowel preparation, and shorter retention of transplant would fail more frequently.

Methods. At our 2-hospital, >1100-bed community-based academic center, we prospectively followed patients pre/post-FMT between June 2014-April 2017. To evaluate factors affecting FMT outcomes, we used 1-sided t-tests to test our hypotheses.

Results. During the study period, 41 patients (mean age 65 ± 17.6 years) underwent FMT. Most (37, 90%) were performed via colonoscopy, 1 via upper GI endoscopy, and 3 via oral preparation (capsules). FMT failure occurred in 10 patients (24.4%). Near half (n = 20) reported AEs, including constipation, gas, abdominal pain, blood in stool, and fatigue. Three patients expired from comorbid disease, and 3 were lost to follow-up. Patients with higher Charlson scores failed more frequently (P = 0.04), and history of tumor (P = 0.03) and pulmonary disease (P = 0.04) were both associated with failure. No other factors, including age, retention time, and Boston bowel prep score, were associated with failure.

Conclusion. This study found that patients with multiple comorbid conditions, as defined by the Charlson index, are at risk for FMT failure. However, quality of bowel prep and retention time did not predict FMT failure. Future studies should include larger samples of FMT patients to determine whether specific comorbidities such as history of tumor and pulmonary disease are clinically significant predictors of FMT failure.

Disclosures. All authors: No reported disclosures.

1264. Cost Effectiveness Analysis of Fecal Transplant Delivery Methods for Recurrent Clostridium difficile Infections in Outpatients Jorge Ramirez Walker, MD1; Nathan Matias Nogueira, MD, FIDSA2; and Ellen Eaton, MD3. Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Infectious Disease, University of Alabama at Birmingham, Birmingham, Alabama; Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Division of Infectious Disease, University of Alabama at Birmingham, Birmingham, Alabama.

Session: 148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM

Background. Clostridium difficile infection (CDI) accounts for more than $1 billion annually in US health care costs. Recurrent CDI (RCDI, recurrence within 8 weeks of initial treatment) contributes substantially to this cost. The objective of this study was to compare the cost effectiveness of FMT delivered via colonoscopy vs. blind nasogastric tube (NGT) in outpatients. We hypothesized that FMT by NGT would be cost-effective given its low risk and simplicity.

Methods. A decision-analytic simulation model compared the cost effectiveness of FMT by colonoscopy vs. NGT from a third-party payer perspective. Our base case cure rates were derived from a cohort receiving outpatient RCDI treatment at our institution. Cure was defined as resolution of symptoms for ≥ 90 days. Procedural cost and consultation was defined by average reimbursment to a large southeastern medical center in 2016 USD based on current procedural terminology (CPT) codes, and cost of disease states were derived from published literature. Health outcomes were defined by quality of life year (QALY) based on published literature. Incremental Cost Effectiveness ratio (ICER) was defined as the cost per additional QALY gained. We assumed a 90 day time horizon. One-way sensitivity analysis was performed on all variables using ranges defined by published literature. We used TreeAge Software (Williamstown, MA).

Results. In the base case, FMT by colonoscopy was dominant (more effective and less costly) than NGT, with cost of $1,586/QALY vs. $1,910/QALY respectively. Cure rates of FMT by colonoscopy vs. NGT (100% vs. 87%) had the largest impact on ICER based on one-way sensitivity analysis. Therefore, a subsequent two-way sensitivity analysis was conducted to compare cure rates of both delivery methods and found that NGT delivery is cost effective as cure rates approach colonoscopy delivery cure rates within 5 percentage points.

Conclusion. Contrary to our hypothesis, our decision model supports FMT by colonoscopy as the preferred delivery method in outpatients with RCDI relative to NGT delivery. Additional costs of colonoscopy delivery are off-set by the improved cure rate leading to lower overall costs. As cure rates from NGT delivery are optimized, NGT may become the preferred FMT delivery method.

Disclosures. All authors: No reported disclosures.

1265. Ribotypes Matter, Significance of Clostridium difficile Ribotypes in Cancer Patients with Diarrhea

Eduardo Yepez Guevara, MD1; Harika Yalamanchili, MD2; Andrew Chao, MD3; Kevin Carey, PharmD, MS, Michal Bhatti, MD, PhD4; Samuel L. Arkin, PharmD5 and Pablo C. Okhuysen, MD, FACP, FIDSA1. Infectious Diseases, University of Texas Health Science Center at Houston – MD Anderson Cancer Center, Houston, Texas; Infectious Disease, The University of Texas Health Science Center at Houston – MD Anderson Cancer Center, Houston, Texas; Infectious Disease, University of Alabama at Birmingham, Birmingham, Alabama; Infectious Disease – Medicine – Anderson Cancer Center, Houston, Texas; University of Houston College of Pharmacy, Houston, Texas; Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas; Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Session: 148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM

Background. Cancer patients are at increased risk for Clostridium difficile infection (CDI) due to frequent health care contact, chemotherapy, use of antibiotics, and immunosuppression. Distinct ribotypes are associated with CDI adverse outcomes. NGT delivery and colonoscopy are the predominant ribotypes in our hands. We examined the contribution of C. difficile ribotypes to CDI severity, response to therapy and outcomes in this population.

Methods. Demographic and clinical data were collected from 90 cancer patients with a first episode or first recurrence of CDI identified by two-step PCR followed by EIA for A/B toxins. Fluorescent PCR ribotyping (FPCR) was performed on fecal isolates. We identified 27 distinct ribotypes between October 2016 and January 2017. Clinical outcomes were studied in three FPCR subgroups. Group I (GI, n = 27) included 10 (37%) and 17 (63%) ribotypes, group II (GII, n = 17) included virulent types 002, 027, 078-126, 244 and group III (GIII, n = 46) included the rest. Treatment failure was defined as no response after at least 3 days of a CDI treatment regimen. CDI severity was determined using Zar’s criteria, presence of bacteriaemia and ICU stay.

Results. The proportion of patients ≥50 yrs. old, with health care onset CDI (31%), primary CDI (92.2%), and on active chemotherapy (70%) was similar across